📄 medicine

Medulloblastoma Management Outcomes: A Multicenter Retrospective Cohort Study from Ethiopia (2018–2025) showing improved early survival despite persistent late decline

This multicenter retrospective study from Ethiopia (2018–2025) demonstrates that while medulloblastoma patients show improved early survival compared to historical data, long-term outcomes remain poor, with gross total resection and older age predicting better survival, whereas brainstem compression, postoperative complications, and delayed radiotherapy significantly increase mortality risk.

Original authors: Alemu Gemeda Bedaso, Sebboona B. Abelti, Yemisirach B. Akililu, Samuel M Fetene, Kedir D. Guduru, Pineal Z. Abera

Published 2026-07-07

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Alemu Gemeda Bedaso, Sebboona B. Abelti, Yemisirach B. Akililu, Samuel M Fetene, Kedir D. Guduru, Pineal Z. Abera

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the brain as a bustling city. In the center of this city, specifically in the "backyard" known as the cerebellum, a very aggressive and dangerous construction crew (the tumor) has set up shop. This crew is called Medulloblastoma. It is the most common type of solid brain tumor found in children, and without a plan to stop it, it can shut down the city's operations very quickly.

This research paper is like a report card from a specific neighborhood in Ethiopia (Addis Ababa) covering the years 2018 to 2025. The researchers looked at 47 children and adults who had surgery to remove this "construction crew." They wanted to see how well the surgery worked, what happened afterward, and who survived the longest.

Here is the story of their findings, broken down into simple parts:

1. The Race Against Time (Survival Rates)

Think of survival as a marathon. In this study, the runners started strong but faced a very steep hill later on.

The Early Finish: Right after surgery (1 month), about 79% of the patients were still running (alive). This is actually a bit better than what doctors in Ethiopia saw in the past.
The Middle Stretch: By 6 months, the number dipped slightly to 76%.
The Long Haul: As time went on, the hill got steeper. By 1 year, less than half (47%) were still running. By 2 years, only 23% remained.
The Finish Line: By 3 years, only 2 people (about 4%) were still in the race. Unfortunately, no one was left running at the 4-year mark.

The Takeaway: The surgery helped people survive the immediate aftermath better than before, but keeping them alive for the long term remains a huge challenge in this setting.

2. The "Surgery" Strategy (How much was removed?)

Imagine the tumor is a sticky patch of gum on a wall. The goal is to scrape it all off without damaging the wall.

The Good News: In about 70% of cases, the surgeons managed to scrape off almost all of the gum (called "Gross Total Resection").
The Result: Patients who had the most gum removed had a much better chance of staying in the race. If the surgeons left a big chunk behind, the risk of the patient passing away increased three times.
The Catch: Even though removing it all is best, it's risky. If the surgeons push too hard near delicate wires (nerves), they can cause new problems.

3. The "Roadblocks" (Complications)

Sometimes, even with a perfect surgery, the road gets blocked. The study found two major roadblocks that made it very hard for patients to recover well:

The Squeezed Engine (Brainstem Compression): The tumor was pressing on the brain's "engine room" (the brainstem) in many patients. If this happened, the patient was 52 times more likely to have a poor outcome. It's like trying to drive a car with the engine crushed.
The Immediate Storm (Post-Op Complications): If the patient got sick or had infections right after surgery (within 48 hours), they were 94 times more likely to have a poor functional outcome. It's like a car breaking down the moment you leave the garage.

4. The "Fuel" (Chemotherapy and Radiation)

After the surgery, the body needs fuel to keep the bad cells from coming back. In this study, the fuel was radiation and chemotherapy.

The Power Combo: Patients who got both radiation and chemotherapy had a massive advantage. Their 1-year survival rate was 100% in the group that got the combo, compared to only 16% for those who didn't get the full treatment.
The Delay Problem: The study noted that many patients waited too long to get this "fuel." In the real world, delays in getting these treatments are like waiting too long to put gas in a car; the engine stops before you get to the destination.

5. What Didn't Matter as Much

The "Type" of Gum: The researchers looked at the tumor under a microscope to see if different "flavors" (types) of the tumor behaved differently. Surprisingly, in this specific group of patients, the type of tumor didn't change the survival outcome. Whether it was "classic" or "desmoplastic," the results were the same.
Age: Whether the patient was a child or an adult didn't significantly change the survival odds in this specific group.

The Bottom Line

This paper tells us that in this Ethiopian setting, surgeons are getting better at the initial operation, removing the tumor more completely than before. However, the "long game" is still very difficult.

To win the race, doctors need to do two things perfectly:

Remove the tumor completely without crushing the brain's engine (brainstem).
Get the patient the "fuel" (radiation/chemo) immediately after surgery without any delays.

Without these two steps working together, the survival rates drop sharply, just like a runner who starts strong but runs out of energy halfway through the marathon.

Technical Summary: Medulloblastoma Management Outcomes in Ethiopia (2018–2025)

Problem Statement
Medulloblastoma is the most common malignant solid brain tumor in children, historically associated with high mortality, particularly in low- and middle-income countries (LMICs) like Ethiopia. While global management protocols have advanced with molecular subtyping and risk stratification, there is a critical lack of local evidence regarding surgical outcomes, functional recovery, and survival rates within the Ethiopian healthcare setting. Previous local data indicated poor survival, but the specific factors driving outcomes—such as the extent of resection, postoperative complications, and access to adjuvant therapy—had not been systematically evaluated in a multicenter cohort to guide clinical practice.

Methodology
This study employed a multicenter retrospective cohort design involving 47 patients with medulloblastoma who underwent operative management between May 1, 2018, and September 30, 2025. The study was conducted at TASH (Black Lion Hospital) and MCM (Zawditu Memorial Hospital) in Addis Ababa, Ethiopia.

Data Collection: Data were extracted from medical records, operation notes, biopsy reports, and imaging (CT/MRI). A convenience sampling technique was used, including all eligible patients who met inclusion criteria (surgery performed, consent obtained, no extra-neural metastasis at presentation) and excluding those with lost follow-up or incomplete records.
Variables: The study analyzed dependent variables (survival, recurrence, functional outcome) against independent variables including age, sex, tumor location, extent of resection (Gross Total Resection [GTR], Near Total Resection [NTR], Subtotal Resection [STR]), histopathological subtype, presence of brainstem compression, immediate postoperative complications, and the timing/intensity of adjuvant therapy (chemotherapy and radiotherapy).
Statistical Analysis: Descriptive statistics summarized patient characteristics. Survival probabilities were estimated using Kaplan–Meier curves and log-rank tests. Cox proportional hazards models (bivariable and multivariable) were used to identify predictors of overall survival (OS), progression-free survival (PFS), and poor functional outcomes. Statistical significance was set at $p < 0.05$ .

Key Results

Survival Trajectory: The study observed a marked decline in survival over time. At 1 month post-surgery, 78.7% (37/47) of patients were alive. This decreased to 76.6% at 6 months, 46.8% at 1 year, 23.4% at 2 years, and only 4.3% at 3 years. No patients survived to the 4-year follow-up mark.
Surgical Outcomes: Gross total resection (GTR) was achieved in 70.2% of patients (33/47). Univariate analysis indicated that less complete resection was associated with a threefold increased hazard of death (HR = 3.0, 95% CI: 1.2–7.5). However, the extent of resection was not significantly associated with progression-free survival (PFS) in the Cox analysis.
Adjuvant Therapy Impact: The receipt of combined chemoradiotherapy was the most decisive factor for survival. Patients receiving both modalities had a 100% 12-month survival rate compared to 16.1% for those who did not. This advantage persisted at 24 months (90.0% vs. 8.0%, $p < 0.001$ ).
Functional Outcomes: Multivariable analysis identified two independent predictors of poor functional outcomes:
1. Brainstem Compression: Patients with compression were approximately 52.5 times more likely to experience poor functional outcomes (AOR = 52.544; 95% CI: 1.754–1574.066).
2. Immediate Postoperative Complications: Patients with immediate complications were approximately 93.9 times more likely to have poor functional outcomes (AOR = 93.887; 95% CI: 1.985–4440.072).
Histopathology and Demographics: The cohort consisted of 80.9% pediatric patients (≤15 years) and 19.1% adults. Histopathological subtypes (Classic, Desmoplastic, Extensive Nodularity) did not show statistically significant differences in survival outcomes at 6 months, 1 year, or 2 years. Age dichotomized at 15 years was not a significant predictor of mortality.

Significance and Claims
The paper claims that while survival outcomes for medulloblastoma in Ethiopia remain suboptimal compared to high-income countries, there is evidence of improved early survival compared to historical local data. The study establishes that in this resource-limited setting, gross total tumor resection and older age at diagnosis are robust independent predictors of favorable survival. Conversely, preoperative brainstem compression, immediate postoperative complications, and delayed initiation of adjuvant oncologic therapy are strong predictors of poor functional and survival outcomes.

The authors conclude that the progressive decline in long-term survival is likely driven by systemic delays in postoperative care and limited access to standardized adjuvant protocols rather than surgical failure alone. The study emphasizes that optimizing surgical strategies to minimize complications and ensuring the timely initiation of multimodal therapy are critical to sustaining the observed early survival gains. The findings underscore the need for tailored protocols in LMIC settings that address both surgical precision and the logistical challenges of delivering comprehensive oncologic care.